IGEN BIOLAB GROUP has established a pipeline of microbiome modulators in clinical phase development that impact in the prevention and treatment of diseases known to be linked at human microbiome dysfunction such as cancer, neurodegenerative and metabolic diseases.

IGEN BIOLAB GROUP R&D facilities include technical areas of In vitro cultivation and testing of microorganisms, mass spectrometry-based proteomics technologies to identify, characterize and quantify target proteins in various biological and biomedical samples, metabolomics for detection and quantification of small molecules (metabolites) in biological materials, microbiomics focusing on using molecular DNA microarray technology to address the complexities of human environmental microbiome ecology.

IGEN BIOLAB GROUP specializes in protein production, bacterial characterization and development of manufacturing processes that are optimized for robust high scale up production. IGEN BIOLAB GROUP commitment to medical progress goes hand in hand with our commitment towards our patients: everyone who might benefit from our findings must have the opportunity to do so. This promise is extended to physicians and the community of all those involved in patient care.